25-Hydroxyvitamin D response to graded vitamin D3 supplementation among obese adults

Andjela Drincic, Eileen Fuller, Robert P. Heaney, Laura A G Armas

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Context: Guidelines have suggested that obese adults need 2 to 3 times more vitamin D than lean adults to treat vitamin D deficiency, but few studies have evaluated the vitamin D dose response in obese subjects. Objective: The purpose of this study was to characterize the pharmacokinetics of 25-hydroxyvitamin D [25(OH)D] response to 3 different doses of vitamin D3 (cholecalciferol) in a group of obese subjects and to quantify the 25(OH)D dose-response relationship. Design, Setting, Intervention, Patients: This was a randomized, single-blind study of 3 doses of oral vitaminD3 (1000, 5000, or 10,000 IU) given daily to 67 obese subjects for 21 weeks during the winter months. Main Outcome Measures: Serum 25(OH)D levels were measured at baseline and after vitamin D replacement, and 25(OH)D pharmacokinetic parameters were determined, fitting the 25(OH)D concentrations to an exponential model. Results: Mean measured increments in 25(OH)D at week 21 were 12.4 ± 9.7 ng/mL in the 1000 IU/d group, 27.8 ± 10.2 ng/mL in the 5000 IU/d group, and 48.1 ± 19.6 ng/mL in the 10,000 IU/d group. Steady-state increments computed from the model were 20.6 ± 17.1, 35.2 ± 14.6, and 51.3 ± 22.0 ng/mL, respectively. There were no hypercalcuria or hypercalcemia events during the study. Conclusion: Our data show that in obese people, the 25(OH)D response to vitamin D3 is directly related to dose and body size with ~2.5 IU/kg required for every unit increment in 25(OH)D (nanograms per milliliter).

Original languageEnglish
Pages (from-to)4845-4851
Number of pages7
JournalJournal of Clinical Endocrinology and Metabolism
Volume98
Issue number12
DOIs
StatePublished - Dec 2013

Fingerprint

Cholecalciferol
Vitamin D
Pharmacokinetics
Single-Blind Method
Vitamin D Deficiency
Hypercalcemia
Body Size
Outcome Assessment (Health Care)
Guidelines
Serum
25-hydroxyvitamin D

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Clinical Biochemistry
  • Endocrinology
  • Biochemistry, medical
  • Endocrinology, Diabetes and Metabolism

Cite this

25-Hydroxyvitamin D response to graded vitamin D3 supplementation among obese adults. / Drincic, Andjela; Fuller, Eileen; Heaney, Robert P.; Armas, Laura A G.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 98, No. 12, 12.2013, p. 4845-4851.

Research output: Contribution to journalArticle

Drincic, Andjela ; Fuller, Eileen ; Heaney, Robert P. ; Armas, Laura A G. / 25-Hydroxyvitamin D response to graded vitamin D3 supplementation among obese adults. In: Journal of Clinical Endocrinology and Metabolism. 2013 ; Vol. 98, No. 12. pp. 4845-4851.
@article{5084c8584f404ae2911f7f08230f45b5,
title = "25-Hydroxyvitamin D response to graded vitamin D3 supplementation among obese adults",
abstract = "Context: Guidelines have suggested that obese adults need 2 to 3 times more vitamin D than lean adults to treat vitamin D deficiency, but few studies have evaluated the vitamin D dose response in obese subjects. Objective: The purpose of this study was to characterize the pharmacokinetics of 25-hydroxyvitamin D [25(OH)D] response to 3 different doses of vitamin D3 (cholecalciferol) in a group of obese subjects and to quantify the 25(OH)D dose-response relationship. Design, Setting, Intervention, Patients: This was a randomized, single-blind study of 3 doses of oral vitaminD3 (1000, 5000, or 10,000 IU) given daily to 67 obese subjects for 21 weeks during the winter months. Main Outcome Measures: Serum 25(OH)D levels were measured at baseline and after vitamin D replacement, and 25(OH)D pharmacokinetic parameters were determined, fitting the 25(OH)D concentrations to an exponential model. Results: Mean measured increments in 25(OH)D at week 21 were 12.4 ± 9.7 ng/mL in the 1000 IU/d group, 27.8 ± 10.2 ng/mL in the 5000 IU/d group, and 48.1 ± 19.6 ng/mL in the 10,000 IU/d group. Steady-state increments computed from the model were 20.6 ± 17.1, 35.2 ± 14.6, and 51.3 ± 22.0 ng/mL, respectively. There were no hypercalcuria or hypercalcemia events during the study. Conclusion: Our data show that in obese people, the 25(OH)D response to vitamin D3 is directly related to dose and body size with ~2.5 IU/kg required for every unit increment in 25(OH)D (nanograms per milliliter).",
author = "Andjela Drincic and Eileen Fuller and Heaney, {Robert P.} and Armas, {Laura A G}",
year = "2013",
month = "12",
doi = "10.1210/jc.2012-4103",
language = "English",
volume = "98",
pages = "4845--4851",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "12",

}

TY - JOUR

T1 - 25-Hydroxyvitamin D response to graded vitamin D3 supplementation among obese adults

AU - Drincic, Andjela

AU - Fuller, Eileen

AU - Heaney, Robert P.

AU - Armas, Laura A G

PY - 2013/12

Y1 - 2013/12

N2 - Context: Guidelines have suggested that obese adults need 2 to 3 times more vitamin D than lean adults to treat vitamin D deficiency, but few studies have evaluated the vitamin D dose response in obese subjects. Objective: The purpose of this study was to characterize the pharmacokinetics of 25-hydroxyvitamin D [25(OH)D] response to 3 different doses of vitamin D3 (cholecalciferol) in a group of obese subjects and to quantify the 25(OH)D dose-response relationship. Design, Setting, Intervention, Patients: This was a randomized, single-blind study of 3 doses of oral vitaminD3 (1000, 5000, or 10,000 IU) given daily to 67 obese subjects for 21 weeks during the winter months. Main Outcome Measures: Serum 25(OH)D levels were measured at baseline and after vitamin D replacement, and 25(OH)D pharmacokinetic parameters were determined, fitting the 25(OH)D concentrations to an exponential model. Results: Mean measured increments in 25(OH)D at week 21 were 12.4 ± 9.7 ng/mL in the 1000 IU/d group, 27.8 ± 10.2 ng/mL in the 5000 IU/d group, and 48.1 ± 19.6 ng/mL in the 10,000 IU/d group. Steady-state increments computed from the model were 20.6 ± 17.1, 35.2 ± 14.6, and 51.3 ± 22.0 ng/mL, respectively. There were no hypercalcuria or hypercalcemia events during the study. Conclusion: Our data show that in obese people, the 25(OH)D response to vitamin D3 is directly related to dose and body size with ~2.5 IU/kg required for every unit increment in 25(OH)D (nanograms per milliliter).

AB - Context: Guidelines have suggested that obese adults need 2 to 3 times more vitamin D than lean adults to treat vitamin D deficiency, but few studies have evaluated the vitamin D dose response in obese subjects. Objective: The purpose of this study was to characterize the pharmacokinetics of 25-hydroxyvitamin D [25(OH)D] response to 3 different doses of vitamin D3 (cholecalciferol) in a group of obese subjects and to quantify the 25(OH)D dose-response relationship. Design, Setting, Intervention, Patients: This was a randomized, single-blind study of 3 doses of oral vitaminD3 (1000, 5000, or 10,000 IU) given daily to 67 obese subjects for 21 weeks during the winter months. Main Outcome Measures: Serum 25(OH)D levels were measured at baseline and after vitamin D replacement, and 25(OH)D pharmacokinetic parameters were determined, fitting the 25(OH)D concentrations to an exponential model. Results: Mean measured increments in 25(OH)D at week 21 were 12.4 ± 9.7 ng/mL in the 1000 IU/d group, 27.8 ± 10.2 ng/mL in the 5000 IU/d group, and 48.1 ± 19.6 ng/mL in the 10,000 IU/d group. Steady-state increments computed from the model were 20.6 ± 17.1, 35.2 ± 14.6, and 51.3 ± 22.0 ng/mL, respectively. There were no hypercalcuria or hypercalcemia events during the study. Conclusion: Our data show that in obese people, the 25(OH)D response to vitamin D3 is directly related to dose and body size with ~2.5 IU/kg required for every unit increment in 25(OH)D (nanograms per milliliter).

UR - http://www.scopus.com/inward/record.url?scp=84889798379&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84889798379&partnerID=8YFLogxK

U2 - 10.1210/jc.2012-4103

DO - 10.1210/jc.2012-4103

M3 - Article

VL - 98

SP - 4845

EP - 4851

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 12

ER -